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Abstract
Background: Lifestyle factors are associated with overall breast cancer risk, but less is known about their associations, alone
or jointly, with risk of specific breast cancer subtypes.
Methods: We conducted a case–control subjects study nested within a cohort of women who participated in the Norwegian
Breast Cancer Screening Program during 2006–2014 to examine associations between risky lifestyle factors and breast cancer
risk. In all, 4402 breast cancer cases subjects with information on risk factors and hormone receptor status were identified.
Conditional logistic regression was used to estimate odds ratios (ORs), with 95% confidence intervals (CIs), in relation to five
risky lifestyle factors: body mass index (BMI) of 25 kg/m2 or greater, three or more glasses of alcoholic beverages per week,
ever smoking, fewer than four hours of physical activity per week, and ever use of menopausal hormone therapy. Analyses
were adjusted for education, age at menarche, number of pregnancies, and menopausal status. All statistical tests were two-
sided.
Results: Compared with women with no risky lifestyle behaviors, those with five had 85% (OR ¼ 1.85, 95% CI ¼ 1.42 to
2.42, Ptrend < .0001) increased risk of breast cancer overall. This association was limited to luminal A–like (OR ¼ 2.20, 95% CI ¼
1.55 to 3.12, Ptrend< .0001) and luminal B–like human epidermal growth factor receptor 2 (HER2)–positive (OR ¼ 1.66, 95% CI ¼
0.61 to 4.54, Ptrend< .004) subtypes. Number of risky lifestyle factors was not associated with increased risk of luminal B–like
HER2-negative, HER2-positive, or triple-negative subtypes (Ptrend> .18 for all).
Conclusions: Number of risky lifestyle factors was positively associated with increased risk for luminal A–like and luminal
B–like HER2-positive breast cancer.
Previous studies have shown that alcohol (1–6), postmeno-
pausal body mass index (BMI) (7), and menopausal hormone
therapy (8–11) are risk factors for breast cancer, whereas physi-
cal activity is a protective factor for breast cancer (12). Smoking
may not be a strong breast cancer risk factor (13–16), but it is
strongly associated with other cancers, and thus must be con-
sidered a risky lifestyle behavior.
Often, risky lifestyle behaviors coexist, and it is therefore im-
portant to combine these behaviors, as opposed to simply look-
ing at them individually, when studying breast cancer risk.
Several studies have reported that the combined effect of risky
lifestyle behaviors is associated with increased mortality overall
(17–21), as well as cancer mortality (22). Very few studies have
investigated the combined effect of lifestyle factors on breast
cancer overall (23–25) or on the risk of specific breast cancer
subtypes (23,26,27). However, although these studies have ex-
amined the association between breast cancer and BMI, food, al-
cohol, smoking, and physical activity (23,25–27), none have
included menopausal hormone therapy use. Further, of the
three studies that examined the effect on subtypes (23,26,27),
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none defined them using the full estrogen receptor (ER)/proges-
terone receptor (PR)/human epidermal growth factor 2 (HER2)
status classification for a more refined stratification.
Breast cancer subtypes, defined as agreed upon at the 2013
St. Gallen Meeting (28), provide the basis for managing early in-
vasive breast cancer. Different subtypes respond to different
treatment regimens, suggesting that they may have a different
biology and possibly also a different etiological profile. The pub-
lished evidence (9,29–34) suggests that luminal A–like cancers
have a hormonal etiology, but the association of hormonal-
related factors with luminal B–like, HER2-positive, and triple-
negative breast cancers is less clear. A large meta-analysis
found stronger positive associations between alcohol and ER-
positive tumors and weaker positive associations between alco-
hol and ER-negative tumors (35), and there is some evidence
that smoking increases the risk of ER-positive and PR-positive
breast tumors (36–39).
Our previous analyses from the Norwegian Breast Cancer
Screening Program (40,41) found that BMI, smoking, alcohol,
physical activity, and menopausal hormone therapy were indi-
vidually associated with breast cancer overall, but the magni-
tude of these associations varied markedly according to ER/PR/
HER2-defined subtypes, the latter taken as surrogates of the St.
Gallen intrinsic subtypes (28). The aim of the present study was
to extend these analyses by examining the combined effect of
these lifestyle factors on risk of breast cancer overall and by ER/
PR/HER2-defined subtypes. The study did not include dietary
factors other than alcohol intake because no strong associations
between such factors and breast cancer risk have been found in
Norway (42,43).
Methods
Study Population
The methods have previously been described in detail (40). In
brief, the Cancer Registry of Norway (CRN) is a population-based
registry that is responsible for the administration of the
Norwegian Breast Cancer Screening Program (NBCSP) (44). The
registry is estimated to be 93.8% complete (45). All women in
Norway age 50 to 69 years are invited to undergo a two-view
mammography screening every two years. The average atten-
dance rate in each round is about 75% (44). Women who
attended the screening during 2006–2014 were asked to com-
plete a questionnaire on a number of standard breast cancer
risk factors before age 50 years and another questionnaire on
current exposure variables at subsequent screenings.
Because of short follow-up, we conducted a matched case–
control subjects study nested within a cohort of 344 348 women
who attended the NBCSP during 2006–2014. Eligible women
were those with no history of breast cancer, any other invasive
cancer (except nonmelanoma skin cancer), or ductal carcinoma
in situ of the breast before January 1, 2006. Participants who ful-
filled these criteria and who had completed the questionnaires
were included in the current study cohort from which cases and
control subjects were identified. Information on cancer ascer-
tainment among cohort members was obtained through linkage
to the CRN records.
Case subjects were women diagnosed with a first occurrence
of invasive breast cancer (ICD10: C50) during 2006–2014, with in-
formation on ER, PR, and HER2 receptor status (see below).
Control subjects had to be cancer free, alive, and residing in the
country at the time of diagnosis. Five control subjects were
individually matched to each breast cancer case subjects by
year of birth (þ/-3 years) and year of last screening (þ/-3 years).
The Regional Committee for Medical and Health Research
Ethics in the South-East Health Region of Norway approved the
study.
If a variable was missing on all the questionnaires a woman
had completed, we excluded her from all analyses. Of the 6471
breast cancer case subjects, we excluded the following due to
missing information on: BMI (n¼ 532), educational level (n¼ 135),
age at menarche (n¼ 229), number of pregnancies (n¼ 164), men-
opausal status (n¼ 59), smoking habits (n¼ 62), alcohol intake
(n¼ 154), and physical activity (n¼ 184). Finally, there were 4952
breast cancer case subjects for analysis. Of the 339 714 remaining
women in the cohort, before we selected control subjects, we ex-
cluded women with missing information on: BMI (n¼ 67 813), ed-
ucational level (n¼ 8362), age at menarche (n¼ 14 818), number
of pregnancies (n¼ 8771), menopausal status (n¼ 6632), smoking
(n¼ 6381), alcohol (n¼ 12 878), and physical activity (n¼ 16 205).
This left us with 197 854 women in the cohort. Of these, we ran-
domly selected five control subjects per case subjects, which left
us with 24 760 control subjects for analysis.
Tumor Receptor Status Ascertainment
Information on ER, PR, and HER2 status, as assessed by immu-
nohistochemistry (IHC), was extracted from pathology reports
submitted to the CRN. Tumors were classified as being ERþ if
they had 10% or greater reactivity from 2006 to January 2012,
and if they had 1% or greater reactivity from February 2012 on-
wards. The change in threshold was a result of a change in
treatment protocols of patients in the clinics in Norway. PRþ
tumors were defined as those with a reactivity of 10% or greater
throughout the study period. Case subjects with no (0) or weak
(1þ) immunostaining were classified as HER2-, whereas case
subjects with strong immunostaining (3þ) were defined as
HER2þ. In situ hybridization was used to confirm HER2 status if
IHC yielded moderate staining (2þ) results. If IHC was 2þ and
fluorescence (FISH), chromogenic (CISH), or silver in situ hybrid-
ization (SISH) was missing, or if IHC was missing but FISH, CISH,
or SISH were positive, the tumor was classified as HER2þ. If IHC
was 2þ and FISH, CISH, and SISH were negative, the tumor was
regarded as HER2-.
We used a modified version of the classification of clinically
defined subtypes proposed at the St. Gallen meeting in 2013
(28). Of the 4952 breast cancer case subjects, 550 case subjects
had unknown hormone receptor status (ie, ER and/or PR) and
HER2 status or could not be classified into subtypes. Of the 4402
breast cancer case subjects, 2761 (63%) were classified as lumi-
nal A–like (ERþPRþHER2-), 709 (16%) as luminal B–like HER2-
negative (ERþPR-HER2-), 367 (9%) as luminal B–like HER2-posi-
tive (ERþPR-/PRþHER2þ), 204 (5%) as HER2-positive (ER-PR-
HER2þ), and 361 (8%) as triple-negative (ER-PR-HER2-).
Risk Factors
Data on the exposures of interest were extracted from the ques-
tionnaires completed at the most recent screening before breast
cancer diagnosis for the case subjects and the corresponding
round for control subjects. Although this is less than ideal for
exposures associated with initiation of cancer, the time point
was chosen to capture recent exposures such as hormone ther-
apy, for which we have previously found strong associations
with breast cancer risk (40,46). The primary exposures of
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interest were BMI, alcohol consumption, smoking habits, physi-
cal activity, and postmenopausal hormone therapy. Weight and
height were self-reported. Women were asked about the amount
of beer, wine, or liquor consumed in glasses per week. The
amount of total alcohol intake was estimated assuming 14 grams
of ethanol per glass of liquor, 20 grams per 0.5 liters of beer, and
12 grams per glass of wine. We converted the alcohol consumed
per week into glasses per week, assuming every glass would have
the same alcohol content as a glass of wine (12 grams). The tables
therefore contain glasses per week estimated as total grams of al-
cohol per week divided by 12 grams of alcohol per glass.
Smoking status was categorized into never, past, and current
smoking. Never smokers were defined as those women who
had never smoked. Women who did not currently smoke but
had smoked in the past were defined as past smokers, and cur-
rent smokers were those women currently smoking. Physical
activity was estimated as number of hours per week of high-in-
tensity physical activity (running, aerobic, or cycling for at least
30 minutes each time) and low-intensity physical activity (walk-
ing, gardening, snow clearing). We added up hours of low- and
high-intensity-level physical exercise into one combined vari-
able. We analyzed high, low, and the combined activity varia-
bles separately, but we only present results for the combined
low and high activity variable. Information on menopausal hor-
mone therapy was examined as never, past, and current use,
and the latter was separated into estrogen alone (ET) and com-
bined estrogen and progestin therapy (EPT).
Creation of the Risky Lifestyle Behavior Variable
We used cut-points to define “risky” for each of the lifestyle fac-
tors based on our previously published results (40,47), that is,
where the risk estimates (odds ratios [ORs]) showed a statisti-
cally significantly elevated risk. To sum up various risky life-
style behaviors, we created binary variables for each behavior
as follows: ever smoking, weekly consumption of more than
three glasses of alcoholic beverage, less than four hours of
physical activity per week, ever use of menopausal
hormone (estrogen or estrogen and progesterone) therapy, and
BMI (25 kg/m2); we made dummy variables of smoking
(0¼never, 1¼ ever), alcohol intake (0 ¼ <3 glasses/wk, 1 ¼ 3
glasses/wk), physical activity (0 ¼ 4 h/wk, 1 ¼ <4 h/wk),
menopausal hormone therapy use (0¼never, 1¼ ever), and BMI
(0 ¼ <25 kg/m2, 1 ¼ 25 kg/m2). The risky lifestyle behavior vari-
able was created as a sum of all the binary variables, with a
resulting range from 0 to 5 risky lifestyle behaviors.
Selection of Confounders
Potential confounders were selected a priori: education (no for-
mal education/primary school, high school, Bachelor’s/
Master’s/higher university education), age at menarche (9–12,
13, 14, 15–18 years), number of pregnancies lasting at least six
months (never, 1, 2, 3, 4), and menopausal status (premeno-
pausal if a woman reported still having a regular menstrual pe-
riod, perimenopausal if she reported irregular periods, and
postmenopausal if she reported that menstruation had stopped
or being on menopausal hormone therapy).
Statistical Analyses
Conditional logistic regression models were fitted to estimate
odds ratios (with 95% confidence intervals [CIs]) as a measure of
association between each individual risk factor, the number of
risky lifestyle behaviors, and breast cancer (overall and by sub-
types), adjusted for confounders.
Trend tests on the original continuous or categorical varia-
bles, as well as on the number of risky lifestyle behaviors, were
performed by fitting ordinal values corresponding to exposure
categories and testing whether the slope coefficient differed
from zero. All analyses were performed using STATA (Stata
Statistical Software: Release 14, StataCorp., College Station, TX).
We considered a two-sided P value of less than .05 statistically
significant.
Sensitivity Analyses
Because of the low numbers in the reference category (0 risky
lifestyle behaviors), we did a sensitivity analysis where we de-
fined the reference category as 0–1 risky lifestyle behaviors.
Many of the other studies on breast cancer subtypes have com-
bined the luminal A–like and luminal B–like HER2-negative sub-
type into one luminal A–like subtype. Therefore, we also
performed a sensitivity analysis where we combined these two
subtypes.
Given that some risk factors, such as overweight/obesity,
have different associations with premenopausal vs postmeno-
pausal breast cancer, we ran a sensitivity analysis excluding
premenopausal women.
Interaction Analyses
To test whether the five lifestyle factors interacted with each
other, we ran statistical analyses to test the interaction between
the binary risky lifestyle factors and breast cancer overall. The
Pinteraction (Pint) value was calculated by modeling interaction
terms (cross-products) between the different binary lifestyle
behaviors and breast cancer overall.
Results
BMI (Ptrend< .0001), intake of alcohol (Ptrend¼ .003), smoking sta-
tus (Ptrend¼ .007), and menopausal hormone therapy use
(Ptrend< .0001) were associated with an increased risk, and phys-
ical activity (Ptrend¼ .02) was associated with a decreased risk
for breast cancer overall (Table 1). Women with a BMI greater
than 28 kg/m2 had a 23% increased risk of breast cancer com-
pared with women with low BMI (22 kg/m2), women who
drank five or more glasses of alcohol beverages a week had a
20% increased breast cancer risk compared with never drinkers,
current smokers had a 13% elevated breast cancer risk com-
pared with never smokers, current users of estrogen and pro-
gesterone therapy had a more than twofold increased breast
cancer risk compared with never users, and women who were
physically active for four or more hours a week had an 11% de-
creased breast cancer risk compared with women who exer-
cised zero hours to one hour per week (Table 1).
Each binary risk factor was associated with a 10%–38%
increase in risk of luminal A–like breast cancer and a non-
statistical 18%–25% increase in risk of breast cancer of luminal
B–like HER2-positive subtype, except for physical inactivity
(Table 2). We found no associations between the binary risk fac-
tors and the other breast cancer subtypes.
When we combined the number of risky lifestyle behaviors,
women with five risky lifestyle behaviors had an 85% increased
risk (95% CI ¼ 1.42 to 2.42) of breast cancer overall compared
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with women with no risky lifestyle behaviors. However, this
risk appeared to be limited to luminal breast cancers. The risk
was strongest for luminal A–like breast cancer (OR¼ 2.20, 95% CI
¼ 1.55 to 3.12), whereas women with five risky behaviors were
at 66% increased risk (95% CI ¼ 0.61 to 4.54) of luminal B–like
HER2-positive breast cancer (Table 3).
In the sensitivity analysis where we defined the reference
category as 0–1 risky lifestyle behaviors, the most important
change was observed for HER2-positive breast cancer, where all
the odds ratios were less than 1 (Supplementary Table 1, avail-
able online).
In the sensitivity analysis where we combined the luminal
A–like and luminal B–like HER2-negative subtype into one lumi-
nal A–like subtype, the results remained largely the same as the
results when we divided luminal A–like and luminal B–like
HER2-negative breast cancers into two different subtypes
(Supplementary Table 2, available online).
In the interaction analyses, the only statistically significant
interaction was between BMI and smoking (Pint¼ .002)
(Supplementary Table 3, available online).
The results for BMI excluding premenopausal women
(OR¼ 1.28, 95% CI ¼ 1.14 to 1.43) remained largely the same as
for the analyses including premenopausal women (OR¼ 1.23,
95% CI ¼ 1.11 to 1.37) when we compared the heaviest (BMI >28
kg/m2) with the leanest women (BMI 22 kg/m2)
(Supplementary Appendix 2, available online), and therefore we
report the results of the analyses including the premenopausal
women.
Discussion
We found that the number of risky lifestyle behaviors was posi-
tively associated with an almost twofold increase in breast can-
cer risk overall. The risk was particularly strong for luminal
A–like and luminal B–like HER2-positive breast cancers. In con-
trast, we found no statistical significant associations between
the number of risky lifestyle behaviors and HER2-positive and
triple-negative breast cancers. However, we observed increased
risk estimates between five risky lifestyle factors and HER2-posi-
tive and triple-negative breast cancers, but these were not statis-
tically significant. Our results suggest that by modifying risky
lifestyle behavior, women could substantially reduce their breast
cancer risk.
Our finding of an effect on breast cancer overall is consistent
with the findings from several other studies (23–25,48). Several
studies have examined the association between healthy life-
style factors and breast cancer subtypes, including the EPIC
study, a Spanish case–control subjects study, and the Vitamins
and Lifestyle (VITAL) cohort study (23,26,27); these studies are
less consistent with our findings on subtypes. The EPIC study
included diet, physical activity, smoking, alcohol consumption,
and anthropometry (23), the Spanish study looked at BMI, phys-
ical activity, diet, alcohol intake, and breastfeeding (26), and the
VITAL study included BMI, physical activity, diet, and alcohol
consumption (27). Our study differed from these previous stud-
ies in that it included use of menopausal hormone therapy, but
it did not include dietary factors other than alcohol in its life-
style index. In our study, we found that women with five risky
lifestyle behaviors had more than a twofold increased risk of lu-
minal A–like breast cancer and a 66% increased risk of luminal
B–like HER2-positive breast cancer compared with women with
no risky lifestyle behaviors. The EPIC study reported that the
least healthy women had a 23% increased risk for both ER-posi-
tive and ER-negative subtypes compared with the more healthy
women (23), the Spanish case–control subjects study reported
that adherence to only three of the nine health recommenda-
tions from World Cancer Research Fund (WCRF)/ American
Institute for Cancer Research (AICR) was associated with a more
than twofold increased risk of luminal A–like and triple-nega-
tive breast cancer and a 64% increased risk of HER2-positive
breast cancer compared with women who followed more than
five of the recommendations (26), and the VITAL cohort study
reported a 16% reduced risk of ER-negative breast cancer and a
10% reduced risk of ER-positive breast cancer for women
Table 1. The association between alcohol, smoking, physical activity,
hormone therapy use, body mass index and breast cancer overall
Breast cancer overall
Case
subjects
Control
subjects OR* (95% CI)
BMI, kg/m2†
22 672 4162 1 (ref)
23–25 1318 7879 1.05 (0.95 to 1.16)
26–28 1175 6343 1.16 (1.04 to 1.29)
>28 1237 6376 1.23 (1.11 to 1.37)
Ptrend <.0001
Alcohol intake per
week, glasses‡
Never drinkers 725 4581 1 (ref)
1 935 5399 1.08 (0.97 to 1.20)
2 850 4853 1.08 (0.97 to 1.21)
3–4 1073 5887 1.11 (1.00 to 1.24)
5þ 819 4040 1.20 (1.07 to 1.35)
Ptrend .003
Smoking§
Never 1748 10 000 1 (ref)
Past 1579 8572 1.07 (0.99 to 1.15)
Current 1075 5726 1.13 (1.03 to 1.23)
Ptrend .007
Physical activity per
week, hk
0–1 712 3758 1 (ref)
2–3 2055 11 000 0.97 (0.88 to 1.07)
4þ 1635 9758 0.89 (0.81 to 0.98)
Ptrend .02
Menopausal hormone
therapy use†
Never 2062 13 000 1 (ref)
Past 1612 8315 1.19 (1.10 to 1.29)
Estrogen current 183 1120 1.08 (0.91 to 1.28)
Estrogen and
progesterone current
224 661 2.23 (1.88 to 2.65)
Ptrend <.0001
*Ptrend and OR mutually adjusted for BMI (22, 23–25, 26–28, >28 at screening),
education (no education/primary school, high school, Bachelor’s and Master’s
þ), age at menarche (9–12, 13, 14, 15–18 years), number of pregnancies (never, 1,
2, 3, 4), and menopausal status (pre-, peri-, postmenopausal). BMI ¼ body mass
index; CI ¼ confidence interval; OR ¼ odds ratio.
†BMI and hormone therapy additionally adjusted for physical activity (never,
1 hour, 2–3 hours, 4–5 hours, 6þ hours), alcohol (never drinkers, 1 glass, 2 glasses,
3–4 glasses, 5þ glasses), and smoking (never, past, and current).
‡Alcohol additionally adjusted for physical activity (never, 1 hour, 2–3 hours,
4–5 hours, 6þ hours) and smoking (never, past, and current).
§Smoking additionally adjusted for alcohol (never drinkers, 1 glass, 2 glasses,
3–4 glasses, 5þ glasses) and physical activity (never, 1 hour, 2–3 hours, 4–5 hours,
6þ hours).
kPhysical activity additionally adjusted for alcohol (never drinkers, 1 glass, 2
glasses, 3–4 glasses, 5þ glasses) and smoking (never, past, and current).
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meeting the WCRF/AICR recommendations compared with
those meeting no recommendations (27).
One explanation of the inconsistent finding between our
study and the EPIC, Spanish, and VITAL studies on the associa-
tion between combined lifestyle factors and ER-negative breast
cancer could be that the latter studies included diet in their life-
style index. The EPIC study looked at the ratio of polyunsatu-
rated to saturated fat intake and intake of fatty fish, margarine,
glycemic load, fruit, and vegetables (23). The Spanish study
looked at the intake of high-density foods, plant foods, and ani-
mal foods (26), and the VITAL study included plant foods and
red and processed meat in the index (27). Dietary factors have
been found to be associated with ER-negative subtype and not
so much with ER-positive breast cancer (49–52). However, a re-
cent study from the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial reported an association between an es-
trogen-related lifestyle score that included some aspects of diet,
in addition to alcohol intake, BMI, and physical activity, and ER-
positive breast cancer (48). The difference between this study
and the EPIC, VITAL, and Spanish studies was that they identi-
fied a dietary pattern specifically associated with high unconju-
gated estradiol (E2) and a low ratio of 2- to 16-hydroxylated
metabolites (2/16).
Another explanation of no findings in our study between
lifestyle factors and HER2-positive and triple-negative breast
cancers could be that we included menopausal hormone ther-
apy in our health index, and previous studies have reported no
association with this risk factor and HER2-positive and triple-
negative breast cancer and a positive association between men-
opausal hormone therapy use and luminal-like breast cancers
(30,33,40).
We did not observe an association between the risky lifestyle
factors examined and luminal B–like HER2-negative breast can-
cer, whereas we found an association with luminal B–like HER2-
positive cancer. This could possibly be due to low power.
Alternatively, it is possible that these risk factors are associated
with HER2þ tumors. HER2 is a transmembrane tyrosine kinase
receptor protein involved in the signal transduction pathways
that lead to cell growth and differentiation (53,54) and overex-
pression of HER2 may disrupt normal cell control subjects
mechanisms, potentially leading to the formation of aggressive
tumor cells (55). It is plausible that the number of risky lifestyle
factors exerts an increased proliferative effect on breast cells if
normal cell control subjects mechanisms have been disrupted
or if overexpression of HER2 has increased the stem/progenitor
cell population. Our results are consistent with a positive,
though not statistically significant, association with the number
of these risk factors and HER2-positive breast cancer.
The only statistically significant interaction we found in our
study was between BMI and smoking. The association between
smoking status (never vs ever) and breast cancer was modified
by BMI. Consistent with our result, a prospective study from the
Women’s Health Initiative reported that the effect of smoking
on the risk of breast cancer was statistically significantly modi-
fied by BMI among postmenopausal women (56). A statistically
significant association between smoking and breast cancer risk
was only found among nonobese women. One possible expla-
nation of the lack of association between smoking and breast
cancer risk among obese women could be through endogenous
estrogen. Early reports have indicated that smoking lowers the
level of estrogen (57), and thus one could hypothesize that the
antiestrogenic effects of smoking may have counterbalanced
the carcinogenic effects of tobacco smoking in the obese smok-
ers compared with the obese nonsmokers (56). However, moreT
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recent studies do not support a strong antiestrogenic effect of
smoking (58,59). Another explanation could be that obese smok-
ers may have a different genetic profile from that of the nonob-
ese smokers; that is, smoking is associated with lower body
weight (60,61). Women who became obese despite smoking
may better metabolize tobacco-related toxins (including carci-
nogens) than leaner smoking women (62).
Strengths and Limitations
Strengths of this study include its population-based design, the
large size, being one of the largest single studies on breast can-
cer subtypes conducted so far, and the availability of prospec-
tively collected detailed information on many risk factors for
breast cancer. Other strengths include complete follow-up and
complete case subjects ascertainment as well as availability of
data on ER, PR, and HER2 receptor status.
Another strength is that we did not combine luminal A–like
subtype with luminal B–like HER2-negative as many other stud-
ies have done. Our results indicated that the number of risky
lifestyle behaviors was associated with luminal A–like but not
luminal B–like HER2-negative breast cancer, suggesting that
these should be treated as two different subtypes.
A limitation of the current study was that we did not include
information on food intake (ie, plant foods, red and processed
meat). Further, women who attend screening might be more
health conscious and have a healthier lifestyle than women
who do not attend. This could have contributed to obliterating
the protective effects of “healthy” habits. At the same time,
women who attend screening are more likely to have their
breast cancers detected. Thus, the picture becomes complicated
with these potential biases, and it is not clear how this could ex-
plain the results of this paper. The associations of well-
established risk factors with overall breast cancer risk were
largely as expected. Furthermore, it is unlikely that any such
bias would have differentially affected the subtype results.
Although this study is one of the largest to date on breast cancer
subtypes, there was limited power for the rare breast cancer
subtypes. Another limitation of the study was that data on risk
factors were self-reported.
In this large nested case–control subjects study, having just
three of the risky lifestyle behaviors was positively associated
with a markedly increased risk for breast cancer overall, which
was limited to luminal A–like breast cancer and luminal B–like
HER2-positive breast cancer. These findings suggest that the
combination of risky lifestyle behaviors may play an important
role in the etiology of some luminal-like breast cancer subtypes.
However, for rarer subtypes, the study may have been
underpowered.
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